Kornimate/medical-research-clean huggingface dataset:
500mg fulvestrant versus everolimus plus exemestane in mbc patients refractory to previous ai

Conditions: Breast Cancer

Summary: 500mg fulvestrant versus everolimus plus exemestane in mbc patients refractory to previous ai

fulvestrant versus everolimus plus exemestane for patients with metastatic breast cancer resistant to aromatase inhibitors: the clinical experience from real -world

Eligibility criteria:
inclusion criteria: 1. patients diagnosed with er/pr+，her2- metastatic breast cancer 2. patients who were refractory to previous aromatase inhibitors 3. patients treated with fulvestrant or everolimus plus exemestane in any line in metastatic setting in fudan university shanghai cancer center，starting from 2013.06.01-2016.06.01 4. available medical history exclusion criteria: 1.incomplete medical history

Keywords: endocrine therapy fulvestrant everolimus
adductor strengthening and pelvic floor muscle strengthening exercises on stress incontinence in gym females

Conditions: Urinary Incontinence, Stress

Summary: stress incontinence is common form of urinary incontinence in females. the theme is to test if pelvic floor muscle training can be augmented by incorporating adductor muscle strengthening. group a: with pelvic floor muscle strengthening plus adductor is strengthening. group b: with pelvic floor muscle strengthening.

stress incontinence is common form of urinary incontinence in females. when it develops in gym doing women, it badly affects their performance and result in psychosocial problems in addition to the barriers that already have been resulted from incontinence. this study combines simple regime of hip adductor a strengthening with pelvic floor muscles. the theme is to test if pelvic floor muscle training can be augmented by incorporating adductor muscle strengthening. if this comes out to be effective, this can be great contribution to gym doing females to improve their urinary incontinence related impairments. woman would be encouraged to continue regular exercise. this will be randomized clinical trial. there are two groups for the compression of adductors strengthening and pelvic floor muscle strengthening. group a: with pelvic floor muscle strengthening plus adductor is strengthening. group b: with pelvic floor muscle strengthening. the collected data will be entered in statistical package for the social sciences 20.0, descriptive and inferential statists will be applied. results and conclusion will be drawn.

Eligibility criteria:
inclusion criteria: * women aged 25-45 years of age * engaged in gym exercises * fulfilling signs and symptoms of stress incontinence exclusion criteria: * pregnant females * females having any history of trauma * any neurological disorders affecting bowl bladder * any malignancy in lower abdominal area

Keywords: urinary incontinence, pelvic floor exercises
evaluation of non-ablative laser for treatment of direct brow lift scars

Conditions: Scar

Summary: the purpose of this study is to determine the efficacy of the 1064nm neodymium yttrium aluminum garnet (nd:yag) laser (laser genesis, cutera tm) in the treatment of surgical scar after direct brow lift.

patients who undergo a direct brow lift may participate in this study. participants will receive laser treatment on one of the two surgical wounds (side of treatment will be chosen randomly by an independent source). treatment parameters will be 500 spots and 10-14 megajoules (mj) depending on skin type. the opposite side brow scar will not be treated until 1 month after the study is completed (if the patient elects to treat the contralateral brow after study completion this will be done at no charge to the patient). this treatment will be given at 2-4 week intervals for 6 treatments. photographs will be taken at each visit, and they will be assessed based on different parameters by an examiner, as well as judged by the patient based on overall appearance.

Eligibility criteria:
inclusion criteria: * undergoing or have undergone direct brow lift exclusion criteria: * under 18 years old * history of photodermatoses * receiving systemic isotretinoin within the preceding 6 months * undergoing other scar treatment in the brow area * pregnant patients * history of adverse outcomes related to non-ablative laser

Keywords: non-ablative laser scar revision direct brow lift
controlling femoral derotation osteotomy in cerebral palsy with electromagnetic tracking

Conditions: Gait Disorders, Neurologic; Cerebral Palsy; Malalignment

Summary: the study is designed to evaluate the use of electromagnetic tracking in transversal plane femoral derotation osteotomies. the goal is to raise the precision of the surgical procedure in order to improve the outcome in short- and long term. all patients are examined with an instrumented 3d gait analysis pre- and one year postoperatively. the electromagnetic tracking system is evaluated against a base line ct or mri scan serving as reference standard pre- and postoperatively.

internal rotation gait is a common deformity in children, especially in those with spastic diplegia. the treatment includes soft tissue and bony correction. especially the bony procedures e.g. femoral derotation osteotomies have proven to be effective both in short term and long term evaluation. nonetheless there is still a relevant number of patients that suffer from over- or under-correction and recurrence over time. the reasons are diverse and include false measurement of the derotation in or. the study now evaluates electromagnetic tracking for femoral derotation to improve these results. the patients are recruited from the outpatients department and included if they meet the criteria. a baseline rotational ct or mri scan and a 3d gait analysis are performed preoperatively. the patients are randomized into a electromagnetic tracking group or a classical goniometer group. the derotation is measured with the emt system or with a classic moeltgen goniometer in the or. goal is to achieve the planned amount of derotation more accurately. the surgical procedure follows standard rules and does not need alterations because of the study. after the operation a second rotational ct or mri scan is performed and the derotation precisely evaluated by two raters and later compared to the results of the intraoperative electromagnetic tracking system. one year postoperative a second 3d gait analysis is performed to measure and compare the functional and dynamic outcome.

Eligibility criteria:
inclusion criteria: * cerebral palsy * gmfcs level i-iii * functionally disturbing internal rotation gait * indication for femoral derotation osteotomy exclusion criteria: * no capacity of consent * inability to perform all needed types examinations * minors: inability of getting a mri rotational scan (i.e. pacemaker)
analysis of emergency department visits according to incidence of covid-19

Conditions: Emergency Service, Hospital; Epidemiology

Summary: with lockdown, emergency departments (ed) visits decrease, principally for visits unrelated with covid-19. in this study, the investigators aimed to find a correlation between ed visits and incidence rate of covid-19 in a french metropolis.

all patients older than 18 years were included in 9 ed during 51 weeks. patients transferred between the centers participating in the study were excluded. the investigators count the number of visits per weeks, then the number of visits according to : * reason for consultation covid-like (cough, fever or dyspnea), * reason for consultation with accordance to french emergency medicine society (sfmu) reference * diagnosis with accordance to sfmu reference * orientation (home, medical unit, chirurgical unit, intensive care unit, psychiatric unit, death) pearson's correlation test compare incidence rate per week with this counts and admission rate.

Eligibility criteria:
inclusion criteria: * patients over 18 years old exclusion criteria: * patient who are transferred between centers participating to the study.

Keywords: non-covid-19 visits emergency departments visits incidence of covid-19
performance status during treatment with pemetrexed in patients with nsclc

Conditions: Non Small Cell Lung Cancer

Summary: the primary research objective of this observational study in pretreated patients with nsclc of stage iiia/b or stage iv is to evaluate patients' karnofsky index (ki) after the second cycle of second-line treatment with single agent pemetrexed in a real life setting, and to evaluate factors potentially influencing performance status in terms of ki, i.e. frequency of use of concomitant medications, in particular analgesics, folic acid, vitamin b12, antiemetics, and medications against diarrhea; as documented in patient diary (days of use per week) and by the physicians.


Eligibility criteria:
inclusion criteria: * are 18 years of age or older * have nsclc, stage iiia/b or iv, that is not amenable to curative therapy * have had one prior chemotherapy regimen with cytotoxic agents for the treatment of nsclc (patients with adjuvant and neoadjuvant regimens are also eligible. however, patients with one prior cytotoxic chemotherapy followed by a targeted agent such as erlotinib are not eligible because the targeted agent would be regarded as second-line treatment) * are initiating second-line of treatment for nsclc with pemetrexed * have been fully informed and have given written consent for the use of their data. exclusion criteria: * have received any prior treatment with pemetrexed * are participating in a study including administration of any investigational drug or procedure at entry into this study
curcumin therapy to treat vascular dysfunction in children and young adults with adpkd

Conditions: Polycystic Kidney, Autosomal Dominant

Summary: the proposed research will determine the effectiveness of curcumin for improving the health and function of arteries in children and young adults with autosomal dominant polycystic kidney disease (adpkd). the study also will provide insight into how curcumin improves artery health by determining the physiological mechanisms (biological reasons) involved and offer exploratory evidence if curcumin can slow kidney growth. this will be done by comparing these measurements in children and young adults who are randomized to receive either curcumin or placebo for 1 year.

although often considered to be a disease of adults, complications of autosomal dominant polycystic kidney disease (adpkd) begin in childhood. while adpkd causes the continued growth of multiple kidney cysts that ultimately result in loss of kidney function, the leading cause of death among patients with adpkd is cardiovascular disease. treatment options to prevent cardiovascular disease in adults with adpkd are limited, thus childhood may be an important time to reduce risk. curcumin is a safe, naturally occurring substance found in the indian spice tumeric, which is in curry powder. the proposed research will determine the effectiveness of curcumin for improving the health and function of arteries in children and young adults with adpkd. the study also will provide insight into how curcumin improves artery health by determining the physiological mechanisms (biological reasons) involved and offer exploratory evidence if curcumin can slow kidney growth. this will be done by comparing these measurements in children and young adults who are randomized to receive either curcumin or placebo for 1 year.

Eligibility criteria:
inclusion criteria: * adpkd diagnosis * normal renal function (estimated glomerular filtration rate \>80 ml/min/1.73m\^2) * ability to provide informed consent exclusion criteria: * currently taking a curcumin supplement * current smoking or history of smoking in the past 12 months * marijuana use within 2 weeks prior to fmdba and apwv testing * antioxidantand/or omega-3 fatty acid use within the past 4 weeks prior to fmdba and apwv testing and for the duration of the study * alcohol dependence and abuse * history of hospitalization within the last 3 months * active infection or antibiotic therapy * pregnancy, lactation, or unwillingness to use adequate birth control * body-mass index \>95th percentile in ages 6-17 or \>40 kg/m2 in ages 18-25 * inability to cooperate with/clinical contraindication for mri including severe claustrophobia, implants, devices, or non-removable body piercings
a study of pyrotinib combined with capecitabine for metastatic her-2 positive colorectal cancer

Conditions: HER-2 Positive Colorectal Cancer

Summary: to evaluate the efficacy and safety of pyrotinib combined with capecitabine in patients with metastatic her-2 positive colorectal cancer after standard treatment.


Eligibility criteria:
inclusion criteria: 1. patients should be histologically diagnosed with metastatic crc and after receiving at least two standard treatment regimens； 2. patients with her2 positive； 3. metastatic colorectal cancer (stage ⅳ, t1-4n0-2m1)； 4. life expectancy is at least 6 months 5. ecog score 0-1； 6. the functional level of the major organs must meet the following requirements (no blood transfusion within 2 weeks prior to screening, no use of leukocytes or platelets)： exclusion criteria: 1. the histopathological type is mucinous adenocarcinoma or ovarian implant metastasis； 2. patients who have previously been treated with anti-her2-targeted drugs； 3. patients with surgical opportunity or potential for surgical treatment； 4. patients with a high risk of bleeding or perforation due to a tumor that has apparently invaded adjacent organs (including large vessels) of the colorectal lesion or who have developed fistulas； 5. patients with any severe and/or uncontrolled disease; 6. patients with any or present brain metastases； 7. women who were pregnant or breast-feeding.
is a positive necpal in icu patients associated with higher mortality

Conditions: Acute Disease

Summary: the aim of the present study is to evaluate the usefulness of the necpal scale in identifying intensive care unit (icu)-admitted patients at higher risk of dying within 90 days of icu admission


Eligibility criteria:
inclusion criteria: * patients who meet all of the following inclusion criteria may be included in the study: * men and women aged 75 years or older. * admission to the icu of the study center. * legal capacity to provide informed consent. * signed informed consent for study inclusion, either by the participant or their legal representative. exclusion criteria: participants who meet any of the following exclusion criteria may not be included in the study: -death within the first 24 hours of icu admission.

Keywords: acute disease intensive care unit
humax-cd4 in non-cutaneous t-cell lymphoma

Conditions: T Cell Lymphoma

Summary: the purpose of this study is to assess the safety and efficacy of treatment of non-cutaneous t-cell lymphoma with treatment with cd4.

the study is closed and all subjects have completed treatment. the study is to evaluate the safety and efficacy of humax cd4 with cho vs cho alone in subjects with non-cutaneous t cell lymphoma. the primary efficacy will be evaluated by time to relapse.

Eligibility criteria:
inclusion criteria: * diagnostic biopsy of non cutaneous t cell lymphoma with positive phenotype * relapsed or refractory to minimum of one course of chemotherapy * study is closed to enrollment.
mirna-155 assay before and after immunotherapy and probiotics

Conditions: Allergic Rhinitis

Summary: the investigators aimed to explore mirna-155 change in response to sublingual immunotherapy (slit), probiotics and combined treatment with slit and probiotics in ar children.

allergic rhinitis (ar) is an inflammatory state characterized by a disturbance of immunoregulatory mechanisms that leads to an amplified t helper "th-2" response. micro-rnas (mirnas) are short single-stranded rna molecules that post transcriptionally control gene expression and can mediate allergic process. the aim of this study was to explore mirna-155 change in response to sublingual immunotherapy (slit), probiotics and combined treatment with slit and probiotics in ar children.

Eligibility criteria:
inclusion criteria: * children aged 5-18 years * diagnosed as having ar * with positive skin test to grass pollen exclusion criteria: * anatomical abnormalities of upper respiratory tract, * previous immunotherapy, * clinically significant inﬂammatory diseases, * malignancies, * chronic treatment with systemic corticosteroids or immune suppressive drugs
technology to enhance treatment for early conduct problems in low income families

Conditions: Disruptive Behavior Disorders

Summary: this study aims to the test the efficacy and cost effectiveness of new service delivery methods to enhance the reach and impact of the standard of care treatment, behavioral parent training (bpt), for early onset disruptive behavior disorders.

families will be randomized to one of two active treatment conditions, the standard bpt program or the standard bpt program plus some new service delivery methods.

Eligibility criteria:
inclusion criteria: * child aged 3 to 7 years * has clinically significant disruptive behaviors * low-income family exclusion criteria: * caregiver has current mood, substance use, and/or psychotic disorder * child has current pervasive developmental and/or psychotic disorder * family has current allegation and/or past substantiation with child protective services

Keywords: disruptive behavior disorders early onset young children parenting behavioral parent training
preventing hiv/sti in urban adolescents via an mhealth primary care intervention

Conditions: HIV/AIDS and Infections; Drug Abuse; Adolescent Behavior; Drug Usage

Summary: the study evaluates the preliminary efficacy of an innovative mobile-health (mhealth) intervention (hereon referred to as s4e) to improve human immunodeficiency virus and sexually transmitted infection testing and reduce hiv/sti risk behaviors in a clinic sample (n=100) of at-risk youth ages 14-21 living in southeast michigan. a stage i randomized control trial will be conducted to examine the preliminary efficacy of s4e, relative to usual care (uc), over a period of six months.

hiv/sti and drug abuse remain significant public health priorities in the us and youth are disproportionately affected. youth between the ages of 15 - 24 constitute 25% of the sexually experienced population, yet account for 46% and 50% of hiv infections and new stis, respectively. national surveillance data indicate that youth disproportionately engage in hiv/sti risk behaviors, including condomless sex and licit and illicit drug use, which increase their risk for hiv/sti infection. despite the disproportionately high rates of hiv/sti infection and risk behaviors in youth, fewer than 14% report having ever been tested for hiv and many are not routinely screened for asymptomatic stis as recommended by the center for disease control. in southeast michigan, hiv/sti are disproportionately high. to address these significant public health concerns, a mobile-health (mhealth) intervention was developed for health clinic settings. the proposed research aims to develop a cross-platform and universal version of s4e. the cross-platform and universal version of s4e will be compatible with both ios and android operating systems, and multiple mobile devices, aimed at providing adolescents with ongoing access to the intervention once they leave the clinic. the proposed research will also evaluate the preliminary efficacy of s4e to improve hiv/sti testing and reduce hiv/sti risk behaviors in a clinic sample (n=100) of at-risk youth ages 14-21 living in southeast michigan by conducting a stage i rct to examine the preliminary efficacy of s4e, relative to usual care, among a sample of 100 at-risk youth over six months.

Eligibility criteria:
inclusion criteria: * female or male youth 14-21 years of age * sexually active * live in southeast michigan * have access to a smartphone or tablet * youth must see an enrolled clinician to participate in the study. exclusion criteria: * report of prior psychiatric hospitalization by adolescent * visible cognitive impairment due to drug use * adolescent reports (tentative or firm) plans to move out of the southeast michigan area during the study

Keywords: mhealth preventive intervention primary health care
vr for the reduction of perioperative anxiety

Conditions: Anxiety State

Summary: the study, set to take place at gold coast university hospital in australia, will be conducted as a randomized controlled trial. patients preparing for gynecological cancer surgery will be recruited and randomly assigned to one of two groups: those who will receive standard care plus a virtual reality (vr) intervention, and those who will receive only standard care. standard care encompasses the usual pre-operative procedures and support provided by the hospital staff. we hypothesize that immersing patients in a preparatory virtual environment that shows them what they are to expect during their upcoming hospital stay for surgery, could help reduce their anxiety levels.

the study objective is to determine whether exposure to the operating theatre suite via virtual reality (vr) for patients undergoing gynecologic-oncological surgery reduces pre-operative anxiety. after patients are recruited, their anxiety level is measured by a simple 6-item visual anxiety scale (t0). patients are then randomized into either receiving care-as-usual (cau), or cau combined with a vr experience (\~3.5 minutes; with background music and narration) where they are familiarized with the environment they will encounter during their stay for their cancer operation. anxiety is measured again (t1). days/weeks later, when patients are back in the hospital for their surgery (t2), anxiety is measured again in the preanesthetic bay, before receiving any anesthetics. personnel collecting the anxiety scale at t2 will be unaware whether a patient had received the vr intervention or not. randomization will be performed by a person unrelated to the study by using a computerized randomization tool to generate an allocation list and inserting paper slips with the group allocation into consecutively numbered, opaque envelopes which are opened, in order, at the time of randomization. using a two-sided wilcoxon-mann-whitney test and targeting a power of 80% at a significance level α of 0.05, abd assuming a clinically relevant difference in the anxiety scale of at least one "face" (i.e. at least 1 point on the 6-item scale) between the two groups and a within-group standard deviation of 1.6 (effect size: 0.625), sample size was determined as 34 patients per group for a 1:1 group allocation. assuming a drop out/lost-to-follow up rate of up to 15%, 80 patients (40 per group) are to be recruited. descriptive statistic analysis will be performed. within-group and between-group assessements will be done using wilcoxon signed rank test and the mann-whitney rank sum test, respectively.

Eligibility criteria:
inclusion criteria: * gynecological oncology patients with scheduled surgery exclusion criteria: * language barrier * inability to provide consent * having undergone any procedure at the operating theatre in the previous 5 years

Keywords: anxiety virtual reality gynecologic-oncological surgery